Amedisys (NASDAQ:AMED) had its price target increased by Royal Bank of Canada from $218.00 to $260.00 in a research report released on Thursday, The Fly reports. They currently have an outperform rating on the health services provider’s stock.
Several other equities analysts also recently commented on the company. SunTrust Banks boosted their price objective on Amedisys from $240.00 to $260.00 and gave the company a buy rating in a research report on Friday, July 10th. Jefferies Financial Group upped their price target on Amedisys from $225.00 to $250.00 and gave the stock a buy rating in a research note on Wednesday. Deutsche Bank increased their price objective on shares of Amedisys from $220.00 to $260.00 and gave the company a buy rating in a report on Thursday. UBS Group lowered their target price on shares of Amedisys from $208.00 to $190.00 and set a neutral rating on the stock in a report on Monday, May 11th. Finally, Oppenheimer restated a buy rating and set a $215.00 target price on shares of Amedisys in a research report on Monday, April 27th. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Amedisys presently has an average rating of Buy and a consensus price target of $215.67.
NASDAQ AMED opened at $234.16 on Thursday. The company has a current ratio of 1.02, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. Amedisys has a 12 month low of $121.00 and a 12 month high of $237.28. The stock has a market cap of $7.58 billion, a price-to-earnings ratio of 60.66, a PEG ratio of 3.44 and a beta of 0.95. The company’s 50 day moving average is $202.10 and its two-hundred day moving average is $187.33.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, July 28th. The health services provider reported $1.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.53. The firm had revenue of $485.06 million for the quarter, compared to the consensus estimate of $468.38 million. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The company’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $1.21 EPS. Sell-side analysts forecast that Amedisys will post 4.84 EPS for the current year.
In other news, insider Denise M. Bohnert sold 362 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $220.00, for a total value of $79,640.00. Following the completion of the sale, the insider now directly owns 9,095 shares of the company’s stock, valued at approximately $2,000,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce D. Perkins bought 2,000 shares of the business’s stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $167.48 per share, for a total transaction of $334,960.00. Following the transaction, the director now owns 28,236 shares in the company, valued at approximately $4,728,965.28. The disclosure for this purchase can be found here. In the last quarter, insiders sold 38,693 shares of company stock valued at $6,882,126. 2.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. APG Asset Management N.V. bought a new stake in shares of Amedisys in the 1st quarter worth about $9,616,000. Northwestern Mutual Wealth Management Co. bought a new position in Amedisys during the 1st quarter valued at about $60,000. Royal Bank of Canada raised its position in Amedisys by 42.8% in the 1st quarter. Royal Bank of Canada now owns 41,113 shares of the health services provider’s stock worth $7,546,000 after purchasing an additional 12,313 shares during the period. Swiss National Bank lifted its stake in Amedisys by 1.8% in the first quarter. Swiss National Bank now owns 62,600 shares of the health services provider’s stock worth $11,490,000 after purchasing an additional 1,100 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in Amedisys by 115.5% in the first quarter. BNP Paribas Arbitrage SA now owns 19,510 shares of the health services provider’s stock worth $3,581,000 after purchasing an additional 10,458 shares during the last quarter. Institutional investors and hedge funds own 88.31% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: What is a CD ladder?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.